TARO vs. ZLAB, AVDL, SUPN, EWTX, KURA, DAWN, ARDX, DVAX, PTGX, and HRMY
Should you be buying Taro Pharmaceutical Industries stock or one of its competitors? The main competitors of Taro Pharmaceutical Industries include Zai Lab (ZLAB), Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), Edgewise Therapeutics (EWTX), Kura Oncology (KURA), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Dynavax Technologies (DVAX), Protagonist Therapeutics (PTGX), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical preparations" industry.
Taro Pharmaceutical Industries (NYSE:TARO) and Zai Lab (NASDAQ:ZLAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.
Taro Pharmaceutical Industries has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
Taro Pharmaceutical Industries currently has a consensus target price of $43.00, indicating a potential upside of 1.15%. Zai Lab has a consensus target price of $64.22, indicating a potential upside of 287.12%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts plainly believe Zai Lab is more favorable than Taro Pharmaceutical Industries.
Taro Pharmaceutical Industries has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Taro Pharmaceutical Industries received 67 more outperform votes than Zai Lab when rated by MarketBeat users. However, 63.58% of users gave Zai Lab an outperform vote while only 61.72% of users gave Taro Pharmaceutical Industries an outperform vote.
Taro Pharmaceutical Industries has a net margin of 7.48% compared to Zai Lab's net margin of -125.46%. Taro Pharmaceutical Industries' return on equity of 3.26% beat Zai Lab's return on equity.
91.4% of Taro Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are owned by company insiders. Comparatively, 5.2% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Zai Lab had 3 more articles in the media than Taro Pharmaceutical Industries. MarketBeat recorded 7 mentions for Zai Lab and 4 mentions for Taro Pharmaceutical Industries. Zai Lab's average media sentiment score of 0.96 beat Taro Pharmaceutical Industries' score of 0.18 indicating that Zai Lab is being referred to more favorably in the news media.
Summary
Taro Pharmaceutical Industries beats Zai Lab on 10 of the 18 factors compared between the two stocks.
Get Taro Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taro Pharmaceutical Industries Competitors List
Related Companies and Tools
